Axxel Knutson Re-iterates "Strong Buy" on Enzo Biochem
Axxel Knutson, CEO of TradingWeapon.com re-iterates his "Strong Buy" recommendation on this debt-free NYSE-listed bio tech.
Warren, NJ (PRWEB) July 27, 2003 -- Enzo Biochem, engaged in the research, development and manufacture of health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community has been reiterated a "Strong Buy" by analyst AXXel Knutson, Chief Investment Officer of TradingWeapon.com.
According to Knutson, Our recommendation of September 24th, 2002 remains very much intact and although the stock is up measurably since that recommendation at $12.99 we think the recent consolidation from the recent high in June of $28.66 offers another buying opportunity in this high quality biotech which is in the relatively unique position of having earnings and no debt on its balance sheet.
Neither the analyst nor his family has a position in this issue. Cantella does not do corporate finance consulting.
Axxel Knutson is President & Chief Investment Officer [CIO] of TradingWeapon.com in Warren, New Jersey, an OSJ* office of Cantella & Co., Inc. an NASD/SIPC member.
| | - Office of Supervisory Jurisdiction
|
For Additional Information, Please Contact:
Axxel Knutson. CEO
Tradingweapon.com
http://www.tradingweapon.com
908-647-5750
axxel@cantella.com
|
